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Abstract
Patient registries are a valuable tool in the research of rare conditions such as pulmonary hypertension (PH). We report
comprehensive hemodynamic and survival data of 174 patients with pulmonary arterial hypertension (PAH) and chronic
thromboembolic pulmonary hypertension (CTEPH), included in the prospective Latvian PH registry over a period of> 9
years. In total, 130 adult PAH patients (75%) and 44 adult CTEPH patients (25%) were enrolled. The median follow-up
period was 33 months for PAH and 18 months for CTEPH, P¼ 0.001. Latvian CTEPH patients had significantly higher
plasma levels of B-type natriuretic peptide, higher pulmonary vascular resistance, and lower cardiac index than Latvian PAH
patients. Calculated incidence of PAH and CTEPH in Latvia in 2016 was 13.7 and 5.1 cases per million inhabitants, calculated
prevalence was 45.7 and 15.7 cases per million inhabitants, respectively. Survival rates at one, three, and five years for PAH
patients was 88.0%, 73.3%, and 58.1%, and 83.8%, 59.0%, and 44.2% for CTEPH patients, respectively. We compared our study
results with data from European adult PH registries. Latvian PAH patients had the fourth lowest and CTEPH patients the lowest
one-year survival rate among European adult PH registries. As most PH registries in Europe are small, yet with equivalent
patient inclusion criteria, it would be desirable to combine these registries to produce more reliable and high-quality study
results.
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Patient registries are one of the key instruments to conduct
research in rare diseases, such as pulmonary hypertension
(PH), because low patient numbers limit the ability to
achieve adequate sample size for epidemiological or clinical
studies.1
There are several examples of successful multinational
collaboration in the field of PH, e.g. the COMPERA regis-
try and international chronic thromboembolic pulmonary
hypertension (CTEPH) registry, proving that large-scale
projects are feasible, albeit with financial support from the
pharmaceutical industry.2,3
However, information about PH registries in Europe that
could potentially collaborate in the future is somewhat lim-
ited. For example, in the latest Orphanet (an organization
providing information about orphan drugs and rare diseases)
report, only three European countries—France,4 Spain,5,6
and Sweden7—are reported as having a PH registry.8
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To our knowledge, this is the first study to report com-
prehensive hemodynamic and transplant-free survival data
from our national referral center (Latvian PH registry) (part
of the data has been published before9–11). Additionally, to
discuss possibility of future collaboration between PH cen-
ters/registries in Europe and to gain a better understanding
of current state of PH registries in the region, we conducted
a systematic literature search to identify prospective studies
based on European adult PH registry data.
Methods
Data collection
This is a single-center prospective observational cohort
study based on incident cases of pulmonary arterial hyper-
tension (PAH) and CTEPH in the Latvian population. The
Latvian PH registry was created in September 2007 at Pauls
Stradins Clinical University Hospital (PSCUH), Riga.
Between 1 September 2007 and 31 December 2016
(9.3 years), 1239 consecutive patients with clinical suspi-
cion of PH were referred to our center from all regions
of Latvia. In total, 683 patients underwent diagnostic right
heart catheterization (RHC) and PH was confirmed in 503
of them. Patients were eligible for enrolment if they met
diagnostic criteria of PAH or CTEPH12 and were
aged 18 years. The date of diagnostic RHC was con-
sidered the date of diagnosis. Patients included in the pre-
sent study were followed until 1 July 2017. Patients who
underwent lung transplantation or pulmonary endarterec-
tomy (PEA) were censored at the time of the surgery; those
lost to follow-up were censored at the time of their last
visit. Based on the etiology of their PH, patients were
divided into PAH subgroups. Diagnosis of CTEPH was
based on contrast-enhanced computed tomography (CT)
and not V/Q scanning because this method is not available
in Latvia.13
Informed consent was obtained from each patient; the
study protocol was in compliance with ethics guidelines of
the Declaration of Helsinki.
The overall incidence and prevalence of PAH and
CTEPH in Latvia was calculated using Latvian population
data in 2016 from the Central Statistical Bureau of Latvia
database (n¼ 1,969,000).14
Statistical analysis
Continuous variables were expressed as mean standard
deviation (SD) or as median with interquartile range
(IQR; Q1–Q3) when data were not normally distributed.
The Kolmogorov–Smirnov test was used to assess normality
of data. Comparison of follow-up period was made using
the Mann–Whitney U test. Categorical variables were
expressed as frequencies and percentages. Survival was esti-
mated using the Kaplan–Meier analysis. P values< 0.05
were considered significant.
Statistical analysis was made using IBM SPSS Statistics
23.0 (IBM Corp., Armonk, NY, USA).
Systematic literature search
We performed a systematic literature search to identify
registry studies in Europe that included adult patients with
PH, PAH, and/or CTEPH and reported registry design,
patient hemodynamic characteristics, and survival. This
was performed on 29 October 2017 in PubMed using the
following search string: (‘‘pulmonary hypertension’’ OR
‘‘pulmonary arterial hypertension’’ OR ‘‘chronic thrombo-
embolic pulmonary hypertension’’) AND (‘‘registry’’ OR
‘‘cohort’’) NOT (pediatric) [All Fields]. Time was restricted
to studies published between January 2000 and October
2017. This search strategy identified 1499 publications.
Studies were considered for inclusion by manual screening
of article titles (and subsequently full articles) to identify
prospective registry studies in relevant populations, pub-
lished in English, and included survival data. Very small
studies (i.e.< 100 patients with PH) were not included in
the analysis. In case of multiple similar (i.e. describing the
same PH group) studies based on the same registry, we
reported the one with largest cohort. In addition to the
three PH registries mentioned in Orphanet report,4–7 ten
prospective European registry studies were in accord with
our inclusion criteria.2,3,15–22 One single-center study (157
patients with PAH and 82 inoperable CTEPH patients)
was excluded from our analysis as it mainly focused on
the presence of atrial flutter and fibrillation and its effect
on patients’ survival.15
Results
A total of 130 PAH and 44 CTEPH patients were enrolled in
our registry by December 2016 and constituted the two main
study groups. Most common PAH subtypes were: idiopathic
PAH (IPAH)¼ 53 patients (41% of all PAH patients); PAH
associated with connective tissue diseases (PAH-CTD)¼ 23
patients (18%); and PAH associated with congenital heart
disease (PAH-CHD)¼ 49 patients (38%). Four patients had
portopulmonary hypertension (PoPH) (3%) and one patient
had drug-induced PAH.
Main demographic, hemodynamic, and other baseline
characteristics in both patient groups are presented in
Table 1. Overall, gender distribution, as well as age
and BMI were similar in both PAH and CTEPH patient
groups, with a majority of patients being women (73%
and 61%, respectively), with median age at the time of
diagnosis of 65 and 67 years, respectively. Both patient
groups had elevated B-type natriuretic peptide (BNP)
indicating advanced disease at the time of diagnosis.
This was partially reflected in patients’ functional
status; the majority of patients in both groups were in
NYHA class III/IV (72% of patients in PAH group and
84% of those in CTEPH group) and had low 6-min
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walking distance (6MWD) (322 122 m and 274 111 m,
respectively).
Apart from two IPAH patients (1% of all patients) who
responded to acute vasodilator testing and received high-
dose calcium channel blockers, all PAH and CTEPH
patients received PH-specific monotherapy after the diagno-
sis, mainly sildenafil (n¼ 123, 71% of all patients). Thirty-
one patients (18%) received bosentan and 18 patients (10%)
received ambrisentan. None of the patients received initial
combination or prostacyclin therapy, as it is currently not
reimbursed in Latvia.
As PEA is not performed in Latvia, only seven Latvian
CTEPH patients underwent PEA (performed in various PH
centers abroad).
Survival
Median follow-up period was 33 months (range¼ 14–54
months) for PAH and 18 months (range¼ 8–34 months)
for CTEPH, P¼ 0.001. Survival rates at one, three, and
five years were 88.0%, 73.3%, and 58.1% for PAH patients,
and 83.8%, 59.0%, and 44.2% for CTEPH patients, respect-
ively. By the end of the study, 40 patients in the PAH group
(30.8%) and 14 in the CTEPH group (31.8%) had died. Two
PAH patients were lost to follow-up and one patient under-
went lung transplantation. Seven CTEPH patients (16%)
underwent PEA. The Kaplan–Meier curve for both patient
groups is illustrated in Fig. 1.
PH registries in Europe
A total of 14 prospective studies based on 12 national and
multinational PH registries were included in our literature
review, representing 18 European countries (17 of them are
member states of the European Union) and Canada (one
center as a part of international CTEPH registry). The
main characteristics of these 12 registries are shown in
Table 2.2–7,16–22 Four of the registries were single-center,
the number of centers in other registries ranged from five
in the Portuguese registry to 31 in the Spanish registry
(REHAP).
The combined PH patient study population was 10,109
(5164 PAH and 3326 CTEPH patients). Three largest stu-
dies represented 44% of combined study population.
All registries had prospective design with inclusion cri-
teria mainly based on international guidelines requiring con-
firmation of PH by RHC: mean pulmonary artery pressure
(mPAP) 25 mmHg at rest; and (for PAH and CTEPH)
pulmonary artery wedge pressure (PAWP) 15 mmHg.
Only the international CTEPH registry permitted inclusion
of patients with mPAP 30 mmHg during exercise, a diag-
nostic criterion, which due to the lack of reliable data was
abandoned by expert consensus in 2009 and not reintro-
duced in the recent PH guidelines.23,24
When analyzing studies by the study cohort, four studies
described only PAH (or its subgroup), three studies
described only CTEPH, four studies described both PAH
and CTEPH patients, and three studies included all five
PH groups. The majority of studies included only adult
patients (aged 18 years); however, the Portuguese and
REHAP registries included patients aged> 14 years, and
both Denmark and Giessen (Gi-PH-Reg) registries did not
specify patient age in their inclusion criteria.
Most studies, being prospective, included only incident
patients; however, REHAP, French, Swiss, and Gi-PH-
Reg registries reported a proportion (range¼ 3–84%) of
patients to whom diagnosis had been established before
enrollment in the registry. Data collection in several regis-
tries (e.g. Gi-PH-Reg, UK, and Ireland registries) was
started in the 1990s; however, most registries were estab-
lished in the 2000s. Study duration was in the range of
1–18.6 years.
In seven studies that included PAH and CTEPH groups,
more patients had PAH than CTEPH. The proportion of
PAH patients in studies was variable, from 58% in the
Portuguese registry to 84% in REHAP. When analyzing
11 studies which included patients with PAH subgroups,
IPAH was the most prevalent subgroup in all studies, with
some registries (e.g. COMPERA) focusing exclusively on
IPAH. The second and third most prevalent PAH sub-
groups were PAH-CTD and PAH-CHD. It is important
to mention that in REHAP, Gi-PH-Reg and French
Table 1. Baseline characteristics of Latvian PAH and CTEPH patients.
Parameters PAH CTEPH
Patients (n (%)) 130 (75) 44 (25)
Female (n (%)) 95 (73) 27 (61)
Age median (years (IQR)) 65 (47–71) 67 (47–73)
BMI (kg/m2) 28.1 7.5 28.5 7.3
BNP (pg/mL (IQR)) 204 (98–413) 340 (181–756)
6MWD (m) 322 122 274 111
NYHA functional class (n (%))
I 2 (2) 0 (0)
II 34 (26) 7 (16)
III 85 (65) 33 (75)
IV 7 (7) 4 (9)
Hemodynamic parameters
RAP (mmHg) 11 7 13 8
mPAP mmHg) 49 18 51 15
PAWP (mmHg (IQR)) 14 (9–15) 12 (8-15)
PVR (WU (IQR)) 6.6 (4.4–10.9) 10.3 (6.9–13.8)
CI (L/min/m2) 2.47 0.73 1.93 0.74
Values are expressed as mean SD or as median with interquartile range (IQR),
where appropriate.
BMI, body mass index; BNP, B-type natriuretic peptide; CI, cardiac index;
CTEPH, chronic thromboembolic pulmonary hypertension; NYHA, New
York Heart Association; 6MWD, 6-min walking distance; RVSP, right ventricular
systolic pressure; PAH, pulmonary arterial hypertension; mPAP, mean pulmon-
ary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary
vascular resistance; RAP, right atrial pressure; WU, Wood units.
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registries,> 20% of all PAH patients did not belong to any
of the three subgroups. In these registries, there was a sig-
nificant proportion of PoPH patients. However, one can
only speculate whether these differences in PAH subgroup
distribution can be explained by referral or diagnostic biases
or they show true epidemiological differences between dif-
ferent registries.
PAH incidence ranged from 0.9 cases in the ASPIRE
registry to 13.7 cases per million inhabitants in Latvia.
The lowest PAH prevalence was reported in France with
15 cases per million adult inhabitants (MAI); however, the
French registry study reported data obtained over a period
of only one year, thereby considerably underestimating true
PAH prevalence in France. The highest PAH prevalence
was observed in Sweden (49 cases/MI) and Latvia (45.7
cases/MI).
Only four registries reported incidence and/or prevalence
of CTEPH. The incidence of CTEPH was approximately
three times lower than that of PAH, ranging from 0.3–3.7
in the ASPIRE registry to 5.1 cases/MI in Latvia. The
lowest CTEPH prevalence was reported in Spain (3.2
cases/MI) and the highest in Sweden (19 cases/MI).
PAH patients
Out of 12 analyzed PH registries, 11 included patients with
PAH or its subgroup. The main patient characteristics of
these 11 registries are presented in Table 3. Female gender
was predominant in all registries, constituting as much as
73% of PAH patients in Latvian registry. Most patients
were diagnosed with reduced functional capacity: NYHA
class III/IV constituted from 69% of all PAH patients in
REHAP to 94% of patients in COMPERA. Only two regis-
tries did not report 6MWD results; the Portuguese registry
did not assess patient exercise tolerance and the ASPIRE
registry used the incremental shuttle walking test, which
was recently proven to be more accurate in assessing exercise
tolerance in PAH patients than the 6MWD.25 However,
methodology and distance covered differ between the two
tests;26 therefore, we did not include these results in the cur-
rent analysis. Despite similarities of studied populations,
there were some notable differences. Age was one of the
parameters that differed the most, youngest patients (pos-
sibly due to younger inclusion age) were reported in
Portuguese and REHAP registries; mean age was 43 16
and 45 17 years, respectively. COMPERA and SPAHR
patients were the oldest at 65 15 and 67 22 years,
respectively.
CTEPH patients
Nine registries included patients with CTEPH. Main patient
characteristics of these nine registries are presented in
Table 4. With the exception of the Latvian registry,
CTEPH patients were generally older than PAH patients
from corresponding registries. However, similar to PAH,
Fig. 1. Kaplan–Meier estimates of cumulative survival from date of diagnosis in Latvian PAH and CTEPH patients.
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most CTEPH patients were already diagnosed with
impaired functional capacity and hemodynamic parameters
were similar both compared to PAH patients and between
CTEPH patients from different registries.
The proportion of patients with PEA differed among the
registries; the lowest proportion (14% of CTEPH patients)
was observed in the Swiss registry which could be explained
by the fact that this registry started to include patients since
1998 when PEA was not widely available and an approved
method of treatment. A similar explanation could be attrib-
uted to Gi-PH-Reg in which the proportion of CTEPH
patients with PEA was 20%. However, the PEA proportion
was quite low in more recently established Portuguese and
Latvian registries (15% and 16%, respectively), possibly due
to the small registry size and consequent lack of patient
volume to safely perform PEA locally.27 The PEA propor-
tion in other registries was from 31% in REHAP to 60% in
the international CTEPH registry and even 100% in the UK
and Ireland registry, confirming that PEA is a recognized
treatment option for CTEPH patients. Both registries that
compared PEA and non-PEA patients (REHAP and
International CTEPH registry) reported that PEA patients
were younger, predominantly male, had higher 6MWD, and
higher mPAP.
Survival
Twelve registries reported at least one-year survival data
(Table 5). Overall, the one-year survival of PAH and
CTEPH patients was similar among registries and between
patient groups, with best survival observed for PEA patients.
Interestingly, the one-year survival rate of 88% in
Latvian PAH and 84% in CTEPH population is the
fourth lowest and lowest in Europe, respectively.
However, due to the relatively short follow-up period (espe-
cially in the Latvian CTEPH group) the three- and five- year
survival data (which also are among the lowest in Europe)
should be interpreted with caution.
Discussion
Comparing our study results with data from other PH regis-
tries in Europe, it is noticeable that most registries had
common patient inclusion criteria, as they were based on
international guidelines, even though guidelines have
slightly changed over time.28–30
Despite the relatively small size of the Latvian PH regis-
try, the observed incidence and prevalence of PAH and
CTEPH in Latvia in 2016 was among the highest in
Europe. This could be attributed to successful informative
campaigning (lectures and scientific conferences for health-
care professionals, events organized by PH patient support
group, etc.) which resulted in a steady increase of newly
diagnosed patients each year up to 27 new PAH and ten
CTEPH patients in 2016.
Age, gender, as well as distribution by PH diagnosis did
not markedly differ between Latvian and European regis-
tries and similarly to Europe, PH patients in Latvia are
diagnosed with more advanced disease and poor functional
status (high NYHA functional class, low 6MWD) and
hemodynamic parameters (high right atrial pressure
(RAP), mPAP, pulmonary vascular resistance, low cardiac
index). The survival of Latvian PAH and CTEPH patients is
among the lowest in Europe.
Although V/Q scan remains the main first-line imaging
modality for CTEPH, contrast-enhanced CT has only












Latvian 59 16 73 26/65/7 322 122 11 7 49 18 8 5 12 4 2.5 0.7
Portuguese16 43 16 65 27/51/20 – 8 6 51 18 11 7 10 4 2.7 1.1
REHAP6 45 17 71 31*/58/11 363 120 9 5 54 16 12 6 – 2.6 0.9
Swedish7 67 22 64 21/68/9 280 (224)y 7 (6)y 45 (16)y 9 (6)y 8 (5)y 2.4 (1.0)y
Danish17 50 21 58 30*/62/8 328 131 10 6 49 15 10 7 11 5 2.4 0.9
Swiss18 57 16 60 24/57/17 362 137 9 4 48 15 9 6 12 7 2.5 0.8
Gi-PH-Reg19 51 16 65 19/59/22 325 126 8 6 51 16 11 (9)y 8 4 2.3 0.8
ASPIREz 20 54 18 70 22*/64/14 – 10 6 48 13 10 6 9 3 2.7 0.9
UK and Ireland§ 21 50 17 70 16*/67/17 292 123 10 6 54 14 13 6 9 4 2.1 0.7
French4 50 15 65 –/75 (III–IV) 329 109 8 5 55 15 – 8 3 2.5 0.8
COMPERA**2 65 15 60 9/75/16 293 126 8 5 44 12 10 6 10 3 2.2 0.7
*NYHA class I–II.
yData presented as median (IQR).
zPatients with pulmonary veno-occlusive disease (n¼ 2) were not included in the analysis.
§IPAH, HPAH, and anorexigen-associated PAH.
**IPAH only.
Abbreviations as in Table 1.
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slightly lower diagnostic accuracy in expert centers (100%
sensitivity, 93.7% specificity, and 96.5% accuracy for V/Q
and 96.1%, 95.2%, and 95.6%, respectively, for CT pul-
monary angiography). Dual-source CT may, in the future,
replace V/Q scanning but has not been widely available in
Latvia. Still, we believe that given the expertise of Latvian
radiologists, the number of Latvian CTEPH cases misdiag-
nosed as IPAH is likely is to be low.
Only 16% of Latvian CTEPH patients underwent PEA,
which is one of the lowest proportions in Europe, translat-
ing into only seven PEA procedures performed over nine
years, despite PEA being the treatment of choice for
CTEPH and demonstrating a positive effect on both patient
quality of life and survival.30
Balloon pulmonary angioplasty (BPA) is an emerging
treatment method for patients with inoperable CTEPH or
patients who have recurrent or persistent PH following
PEA.30,31 None of the analyzed registries reported patients
with BPA; however, its role in the future will likely increase
as there is accumulating evidence that BPA leads to hemo-
dynamic and functional improvements. Several randomized
controlled trials comparing BPA with targeted medical ther-
apy (riociguat) are underway.31
Given the low CTEPH patient survival in our country, it
is clear that Latvia has to make an increased effort in pro-
viding evidence-based care for patients with CTEPH who
could benefit from PEA and/or BPA.
Our center is the only PH reference center in Latvia and
all diagnostic workups and treatment of PH patients is done
in-house. Although this ensures that all patients diagnosed
with PAH or CTEPH are included in the Latvian PH regis-
try, patients with suspicion of PH may never be referred
from local hospitals, therefore influencing reported inci-
dence and prevalence of PAH and CTEPH as well as sur-
vival estimates in our study.
Current results are limited by the small study population
and the observational study design, which creates unmeas-
ured confounders and potential selection bias. Therefore,
comparison between registries must be made with caution.
More efforts should be made towards a wider collabor-
ation between countries/regions as new global clinical data
on rare diseases, would permit to gain new insights on a
broader range of PH types (prevalence of which differs
between developed and developing countries) and would
also allow to design more representative and purposeful
clinical trials, therefore advancing the knowledge on PH
and ultimately improving the quality of care.1,32,33
As numerous PH registries in Europe are small and
patient inclusion criteria are practically the same, it would
be reasonable to combine efforts and combine PH patient
populations from multiple registries, therefore gaining more
high-quality data and results.
Various approaches are possible to move towards such
globalization of PH registries, including a recent creation of
web-based Global Rare Diseases Patient Registry Data
























































































































































































































































































































































































































































































































































































































































































































































































































Pulmonary Circulation Volume 8 Number 3 | 7
program and Pulmonary Hypertension Association Registry
(PHAR), a multi-center prospective registry across> 30 PH
centers in the USA.33–35 A viable alternative could be net-
working (e.g. recently created European Reference
Networks or ERNs) with future unification of national or
regional PH registries using a common or overlapping case
report forms and comparable enrollment principles while
keeping their own funding sources and management.33
From a technical standpoint, a latter model would either
require: (1) to develop a web-based software for manage-
ment of PH registry data, which could then become as a
standard tool for collaboration (e.g. iPHnet project
in Italy);36 and (2) to join a group of PH centers/national
registries (Portugal, France, Netherlands, etc.), and acquire
a commercial, standardized web-based PH database
(PAHtool, Inovultus, Portugal).16,37,38
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